Losartan in postmenopausal women with essential arterial hypertension

Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihyper...

Full description

Bibliographic Details
Main Authors: O. N. Tkacheva, A. V. Barabashkina, I. M. Novikova, N. V. Sharashkina
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2010-12-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/2141
_version_ 1797882672569122816
author O. N. Tkacheva
A. V. Barabashkina
I. M. Novikova
N. V. Sharashkina
author_facet O. N. Tkacheva
A. V. Barabashkina
I. M. Novikova
N. V. Sharashkina
author_sort O. N. Tkacheva
collection DOAJ
description Aim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.
first_indexed 2024-04-10T03:38:25Z
format Article
id doaj.art-7583c3ea53714e26875299df90356076
institution Directory Open Access Journal
issn 1728-8800
2619-0125
language Russian
last_indexed 2024-04-10T03:38:25Z
publishDate 2010-12-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj.art-7583c3ea53714e26875299df903560762023-03-13T07:23:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-12-019625311850Losartan in postmenopausal women with essential arterial hypertensionO. N. Tkacheva0A. V. Barabashkina1I. M. Novikova2N. V. Sharashkina3ФГУ “Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Минздравсоцразвития”. МоскваВладимирская областная клиническая больница. ВладимирФГУ “Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Минздравсоцразвития”. МоскваФГУ “Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Минздравсоцразвития”. МоскваAim. To study losartan effectiveness and safety in postmenopausal women with essential arterial hypertension (EAH), and with or without hormone replacement therapy (HRT). Material and methods. In total, 58 postmenopausal women with EAH were followed up for 6 months after being administered antihypertensive therapy (AHT) with losartan, due to inadequate blood pressure (BP) control. Group I (n=30) did not receive HRT, while Group II (n=28) was administered HRT. Losartan effects on BP dynamics, endothelium-dependent vasodilatation (EDVD), intima-media thickness (IMT) of carotid arteries (CA), lipid and carbohydrate metabolism were assessed, as well as losartan tolerability. Results. Losartan therapy resulted in target BP level achievement in both groups. At the study end, EDVD increase was statistically significant in Group I (р<0,05) and highly significant in Group II (р<0,001). In both groups, a tendency towards CA IMT reduction was observed. In all participants, a positive dynamics of lipid profile was observed, but it reached statistical significance only for low-density lipoprotein cholesterol in Group II. After 6 months, insulin sensitivity was normalized in all patients. The tolerability of losartan was good throughout the study period. Conclusion. In postmenopausal women with AH, adding losartan to the AHT scheme demonstrated good antihypertensive effectiveness, insulin sensitivity normalization, endothelial function and lipid profile improvement. Among women receiving AHT and HRT, antihypertensive effect, as well as beneficial effects on endothelial function and lipid profile, was greater than in women receiving AHT only.https://cardiovascular.elpub.ru/jour/article/view/2141артериальная гипертонияпостменопаузалозартан
spellingShingle O. N. Tkacheva
A. V. Barabashkina
I. M. Novikova
N. V. Sharashkina
Losartan in postmenopausal women with essential arterial hypertension
Кардиоваскулярная терапия и профилактика
артериальная гипертония
постменопауза
лозартан
title Losartan in postmenopausal women with essential arterial hypertension
title_full Losartan in postmenopausal women with essential arterial hypertension
title_fullStr Losartan in postmenopausal women with essential arterial hypertension
title_full_unstemmed Losartan in postmenopausal women with essential arterial hypertension
title_short Losartan in postmenopausal women with essential arterial hypertension
title_sort losartan in postmenopausal women with essential arterial hypertension
topic артериальная гипертония
постменопауза
лозартан
url https://cardiovascular.elpub.ru/jour/article/view/2141
work_keys_str_mv AT ontkacheva losartaninpostmenopausalwomenwithessentialarterialhypertension
AT avbarabashkina losartaninpostmenopausalwomenwithessentialarterialhypertension
AT imnovikova losartaninpostmenopausalwomenwithessentialarterialhypertension
AT nvsharashkina losartaninpostmenopausalwomenwithessentialarterialhypertension